UBS Group’s Pardes Biosciences, Inc. Common Stock PRDS Stock Holding History

UBS Group’s Portfolio PRDS Stock Details PRDS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-339	Closed	-$614	–	10264
2023 Q2	$614	Sell	339 -10,967	-97%	-$20.1K	﹤0.01%	8164
2023 Q1	$14.9K	Sell	11,306 -4,921	-30%	-$8.05K	﹤0.01%	7314
2022 Q4	$27.4K	Sell	16,227 -11,013	-40%	-$14K	﹤0.01%	7335
2022 Q3	$50K	Buy	27,240 +3,576	+15%	+$10.7K	﹤0.01%	6359
2022 Q2	$72K	Buy	23,664 +23,514	+15,676%	+$144K	﹤0.01%	5664
2022 Q1	$1K	Hold	150	–	–	﹤0.01%	10034
2021 Q4	$2K	Sell	150 -35	-19%	-$407	﹤0.01%	9877
2021 Q3	$2K	Sell	185 -1,465	-89%	-$14.6K	﹤0.01%	9038
2021 Q2	$16K	Buy	+1,650	New	+$16.6K	﹤0.01%	7599

Other funds holding PRDS

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

UBS Group's PRDS Position: Q3 2023 in Review

UBS Group sold out of Pardes Biosciences, Inc. Common Stock (PRDS) in Q3 2023, closing a stake of 339 shares — an estimated $614 sold.

UBS Group first reported a position in PRDS in Q2 2021 and held it in 9 quarters. The position peaked at $72K in Q2 2022. 1 fund tracked by Wall St. Rank holds PRDS as of Q3 2023.

UBS Group reported no remaining Pardes Biosciences, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
UBS Group sold 339 Pardes Biosciences, Inc. Common Stock shares in Q3 2023, an estimated $614.
UBS Group first reported a position in Pardes Biosciences, Inc. Common Stock in Q2 2021 and held it in 9 quarters.
UBS Group's Pardes Biosciences, Inc. Common Stock position peaked at $72K in Q2 2022.
1 fund tracked by Wall St. Rank held Pardes Biosciences, Inc. Common Stock as of Q3 2023.

Based on UBS Group's 13F filing for Q3 2023, filed 9 Nov 2023.